Auris Medical Gets $51M For Hearing Disorder Drugs

Sheridan, Cormac
April 2013
BioWorld International;4/17/2013, Vol. 18 Issue 16, p1
The article reports that biotechnology firm Auris Medical AG received 50.8 million U.S. dollars in a Series C funding from Sofinnova Ventures and Sofinnova Partners. The funding will be allocated to study lead drug candidates, AM-101 and AM-111 for acute tinnitus and acute inner ear hearing loss, respectively. According to Thomas Meyer, founder and managing director of Auris Medical, the company is in special protocol assessment process with the U.S. Food and Drug Administration (FDA).


Related Articles

  • Auris Medical Gets $51M For Hearing Disorder Drugs. Sheridan, Cormac // BioWorld Today;4/17/2013, Vol. 24 Issue 73, p1 

    The article reports that Switzerland-based Auris Medical AG has landed 50.8-million U.S.-dollars in a 2013 Series C funding from Sofinnova Ventures and Sofinnova Partners, representing one of Europe's largest biotech private equity deals. The funding will take forward Auris Medical's 2 lead drug...

  • Some of the latest hearing industry news from HearingReview.com.  // Hearing Review Products;Sep2012, Vol. 11 Issue 5, p6 

    This section offers news briefs on the hearing care industry. Six hearing aid manufacturers formed the Hearing Industry Research Consortium (IRC) to develop and direct a research agenda designed to benefit the industry, hearing professionals and end users. Forty patients enrolled in the first...

  • Phase II Data Keep M-101 On Track for Pivotal Trials. Sheridan, Cormac // BioWorld International;9/11/2013, Vol. 18 Issue 37, p2 

    The article reports that Auris Medical AG has completed the second Phase II trial of its lead compound tinnitus drug AM-101. The study was conducted among 85 patients with bilateral tinnitus who randomly received a placebo, a single-dose treatment of AM-101 or a triple-dose regimen over a...

  • Financings Roundup.  // BioWorld Today;12/14/2007, Vol. 18 Issue 242, p6 

    This article reveals the amount raised by Ascendis Pharma A/S in a Series A round led by Sofinnova Partners and co-led by Gilde Healthcare Partners. Proceeds will be used to broaden the company's pipeline, which is based on a transient linker technology platform. The platform is designed to...

  • Joining forces.  // Nature Biotechnology;Nov2009, Vol. 27 Issue 11, p959 

    The author discusses the tendency of technology incubators to look for new technology beyond their own borders to be able to survive the current stringent investment climate. The author cites the case of venture capital company Sofinnova Partners to illustrate how hard it is for life science...

  • Around the world in a month.  // Nature Biotechnology;May2012, Vol. 30 Issue 5, p382 

    This section offers news related to the biotechnology field including a plan by the Swedish government to inject record funding into SciLifeLab, opening by Sofinnova Ventures of a new office in Ireland, and the research collaboration signed between Sanofi and the Center for Genomic Regulation in...

  • Hearing Help. YANDELL, KATE // Scientist;Sep2015, Vol. 29 Issue 8, p43 

    The article focuses on several drugs and therapies being developed by researchers that could rebuild hair cells and treat hearing loss. Topics include two Phase 3 clinical trials conducted by biotechnology firm Auris Medical for testing a drug called AM-111 for the treatment of sudden hearing...

  • Top Financings Of Private Companies: 2013.  // BioWorld Insight;7/8/2013, Vol. 21 Issue 28, p14 

    Two tables related to top financings of private biotechnology companies including Intrexon Corp., Ophthotech Corp. and Auris Medical AG are presented and provides information on their location and amount of money.

  • Top Financings Of Private Companies: 2013.  // BioWorld Insight;5/6/2013, Vol. 21 Issue 19, p13 

    A table is presented depicting the finance of private biotechnology companies located in the U.S. in 2013 including Auris Medical AG, Jounce Therapeutics Inc. and Opsona Therapeutics Ltd.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics